Schroder Investment Management Group Has $22.95 Million Stock Position in Exelixis, Inc. $EXEL

Schroder Investment Management Group lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 32.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 565,615 shares of the biotechnology company’s stock after selling 276,009 shares during the period. Schroder Investment Management Group owned 0.21% of Exelixis worth $22,947,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. AQR Capital Management LLC increased its holdings in Exelixis by 10.3% in the second quarter. AQR Capital Management LLC now owns 7,606,079 shares of the biotechnology company’s stock valued at $335,238,000 after purchasing an additional 712,190 shares during the period. Geode Capital Management LLC lifted its holdings in Exelixis by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock worth $328,196,000 after buying an additional 28,289 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Exelixis by 42.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock worth $231,951,000 after buying an additional 1,580,567 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Exelixis by 11.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock valued at $172,658,000 after buying an additional 419,596 shares during the last quarter. Finally, Assetmark Inc. increased its stake in shares of Exelixis by 1,230.8% in the third quarter. Assetmark Inc. now owns 3,195,971 shares of the biotechnology company’s stock valued at $131,994,000 after buying an additional 2,955,813 shares during the period. Institutional investors own 85.27% of the company’s stock.

Exelixis Price Performance

Shares of Exelixis stock opened at $41.17 on Friday. The stock’s 50-day moving average is $43.36 and its 200 day moving average is $41.64. Exelixis, Inc. has a one year low of $32.38 and a one year high of $49.62. The firm has a market cap of $10.69 billion, a price-to-earnings ratio of 14.86, a PEG ratio of 0.94 and a beta of 0.41.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. During the same period in the previous year, the company posted $0.55 earnings per share. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Wolfe Research started coverage on Exelixis in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Truist Financial set a $51.00 price target on shares of Exelixis in a report on Wednesday, January 14th. Bank of America downgraded shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price target on the stock. in a research report on Monday, January 5th. Finally, Wells Fargo & Company upped their price objective on shares of Exelixis from $30.00 to $35.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 11th. Ten investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Exelixis currently has a consensus rating of “Hold” and an average price target of $46.94.

Insider Activity at Exelixis

In other news, EVP Patrick J. Haley sold 67,814 shares of Exelixis stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $43.52, for a total value of $2,951,265.28. Following the completion of the sale, the executive vice president owned 381,908 shares in the company, valued at $16,620,636.16. The trade was a 15.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Dana Aftab sold 47,918 shares of the business’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $44.50, for a total transaction of $2,132,351.00. Following the transaction, the executive vice president owned 616,106 shares in the company, valued at $27,416,717. The trade was a 7.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 362,849 shares of company stock worth $15,917,463. Corporate insiders own 2.82% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.